<VariationArchive VariationID="1695419" VariationName="NM_000183.3(HADHB):c.693del (p.Ala232fs)" VariationType="Deletion" Accession="VCV001695419" Version="2" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-06-23" DateCreated="2022-07-18" MostRecentSubmission="2022-07-18">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1687830" VariationID="1695419">
      <GeneList>
        <Gene Symbol="HADHB" FullName="hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta" GeneID="3032" HGNC_ID="HGNC:4803" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>2p23.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="26244939" stop="26290465" display_start="26244939" display_stop="26290465" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="26467615" stop="26513332" display_start="26467615" display_stop="26513332" Strand="+" />
          </Location>
          <OMIM>143450</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_000183.3(HADHB):c.693del (p.Ala232fs)</Name>
      <CanonicalSPDI>NC_000002.12:26279195:CC:C</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>2p23.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="26279196" stop="26279196" display_start="26279196" display_stop="26279196" variantLength="1" positionVCF="26279195" referenceAlleleVCF="GC" alternateAlleleVCF="G" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="26502064" stop="26502064" display_start="26502064" display_stop="26502064" variantLength="1" positionVCF="26502063" referenceAlleleVCF="GC" alternateAlleleVCF="G" />
      </Location>
      <OtherNameList>
        <Name>g.36028del</Name>
        <Name>p.A232Lfs*20</Name>
      </OtherNameList>
      <ProteinChange>A210fs</ProteinChange>
      <ProteinChange>A217fs</ProteinChange>
      <ProteinChange>A232fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000002.11" sequenceAccession="NC_000002" sequenceVersion="11" change="g.26502065del" Assembly="GRCh37">
            <Expression>NC_000002.11:g.26502065del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000002.12" sequenceAccession="NC_000002" sequenceVersion="12" change="g.26279197del" Assembly="GRCh38">
            <Expression>NC_000002.12:g.26279197del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_007294.1" sequenceAccession="NG_007294" sequenceVersion="1" change="g.39245del">
            <Expression>NG_007294.1:g.39245del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000183.3" sequenceAccession="NM_000183" sequenceVersion="3" change="c.693del" MANESelect="true">
            <Expression>NM_000183.3:c.693del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000174.1" sequenceAccession="NP_000174" sequenceVersion="1" change="p.Ala232fs">
            <Expression>NP_000174.1:p.Ala232fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001281512.2" sequenceAccession="NM_001281512" sequenceVersion="2" change="c.648del">
            <Expression>NM_001281512.2:c.648del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001268441.1" sequenceAccession="NP_001268441" sequenceVersion="1" change="p.Ala217fs">
            <Expression>NP_001268441.1:p.Ala217fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001281513.2" sequenceAccession="NM_001281513" sequenceVersion="2" change="c.627del">
            <Expression>NM_001281513.2:c.627del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001268442.1" sequenceAccession="NP_001268442" sequenceVersion="1" change="p.Ala210fs">
            <Expression>NP_001268442.1:p.Ala210fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="2147825515" DB="dbSNP" />
      </XRefList>
      <FunctionalConsequence Value="RNA degradation by nonsense-mediated decay">
        <XRef ID="0347" DB="Variation Ontology" />
      </FunctionalConsequence>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000183.3(HADHB):c.693del (p.Ala232fs) AND Mitochondrial trifunctional protein deficiency" Accession="RCV002264901" Version="2">
        <ClassifiedConditionList TraitSetID="2402">
          <ClassifiedCondition DB="MedGen" ID="C1969443">Mitochondrial trifunctional protein deficiency</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-04-20" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-04-20" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2022-07-18" MostRecentSubmission="2022-07-18">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">12754706</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="2402" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="9419" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Mitochondrial trifunctional protein deficiency</ElementValue>
                <XRef ID="MONDO:0012172" DB="MONDO" />
                <XRef ID="237999008" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">TFP</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="3684" />
                <XRef ID="3684" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Long-chain hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency and trifunctional protein (TFP) deficiency are caused by impairment of mitochondrial TFP. TFP has three enzymatic activities – long-chain enoyl-CoA hydratase, long-chain 3-hydroxyacyl-CoA dehydrogenase, and long-chain 3-ketoacyl-CoA thiolase. In individuals with LCHAD deficiency, there is isolated deficiency of long-chain 3-hydroxyacyl-CoA dehydrogenase, while deficiency of all three enzymes occurs in individuals with TFP deficiency. Individuals with TFP deficiency can present with a severe-to-mild phenotype, while individuals with LCHAD deficiency typically present with a severe-to-intermediate phenotype. Neonates with the severe phenotype present within a few days of birth with hypoglycemia, hepatomegaly, encephalopathy, and often cardiomyopathy. The intermediate phenotype is characterized by hypoketotic hypoglycemia precipitated by infection or fasting in infancy. The mild (late-onset) phenotype is characterized by myopathy and/or neuropathy. Long-term complications include peripheral neuropathy and retinopathy.</Attribute>
                <XRef ID="NBK583531" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">36063482</ID>
                <ID Source="BookShelf">NBK583531</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/C16-OH-C18-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, LCHAD/TFP: C16-OH Elevated +/-C18-OH, 2022</CitationText>
              </Citation>
              <XRef ID="746" DB="Orphanet" />
              <XRef ID="C1969443" DB="MedGen" />
              <XRef ID="MONDO:0012172" DB="MONDO" />
              <XRef Type="Phenotypic series" ID="PS609015" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="4984950" SubmissionDate="2022-07-11" DateLastUpdated="2022-07-18" DateCreated="2022-07-18">
        <ClinVarSubmissionID localKey="SUB11779637" submittedAssembly="GRCh38" title="SUB11779637" />
        <ClinVarAccession Accession="SCV002546245" DateUpdated="2022-07-18" DateCreated="2022-07-18" Type="SCV" Version="1" SubmitterName="Vockley Lab, University of Pittsburgh" OrgID="508178" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-04-20">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation Type="general">
            <ID Source="PubMed">12754706</ID>
          </Citation>
          <Comment>The point deletion with frameshift variant c.693delC in exon 9 (p.A232Lfs*20) has been initially described by Spiekerkoetter et al. (2003) in the same patient as the present submission. It was found in a compound heterozygous state with the missense variant c.881C&gt;G (p.P294R) in exon 10. They described the patient as a male Caucasian patient presenting the hepatic form of the disease, who was 5-month old at the onset and 1-year-5-month old when the paper was published – in the latter occasion he was asymptomatic. In the patient description, the authors refer hypoglycemia, but not cardiomyopathy, skeletal myopathy, neuropathy or maternal HELLP syndrome.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation Type="general">
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Ethnicity>Euro-American</Ethnicity>
              <GeographicOrigin>United States of America</GeographicOrigin>
              <Species TaxonomyId="9606">human</Species>
              <Age Type="minimum" age_unit="years">20</Age>
              <Age Type="maximum" age_unit="years">29</Age>
              <AffectedStatus>yes</AffectedStatus>
              <Gender>male</Gender>
            </Sample>
            <Method>
              <TypePlatform>Sanger sequencing</TypePlatform>
              <Description>DNA was extracted from cultured fibroblasts. Information on primers was kindly provided by Dr. Lodewijk IJlst, Amsterdam, Netherlands. The exons and adjacent intronic regions of HADHA and HADHB were amplified by PCR. PCR products were column purified and then sent to an external facility for Sanger DNA sequencing (Genewiz, Inc; South Plainfield, NJ). The sequence was assembled with the reference sequence NG_007294.1 by CLC Main Workbench 8.</Description>
              <MethodType>research</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="CompoundHeterozygote" integerValue="1" />
            </ObservedData>
            <TraitSet DateLastEvaluated="2021-07-01" Type="Finding">
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0001252" />
              </Trait>
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0003201" />
              </Trait>
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0009830" />
              </Trait>
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0001985" />
              </Trait>
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0003236" />
              </Trait>
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0045045" />
              </Trait>
            </TraitSet>
          </ObservedIn>
          <ObservedIn>
            <Sample>
              <Origin>not applicable</Origin>
              <Tissue>Skin fibroblasts</Tissue>
              <CellLine>FB861</CellLine>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>not applicable</AffectedStatus>
              <Gender>male</Gender>
            </Sample>
            <Method>
              <Description>Skin fibroblasts were incubated with [9,10-3H]oleate for 1.5 hours. After incubation, 3H2O released was separated from the oleate on a column containing an anion exchange resin. The results of replicates of the affected individual fibroblasts were compared to control fibroblasts.</Description>
              <MethodType>in vitro</MethodType>
              <ObsMethodAttribute>
                <Attribute Type="MethodResult">Significant reduction of tritium release (0.075 nmol/hr/mg of protein/mL) from tritiated oleate compared to control fibroblasts (0.521 nmol/hr/mg of protein/mL).</Attribute>
              </ObsMethodAttribute>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
            <Comment>The result demonstrates an important impairment of long-chain fatty acid beta-oxidation.</Comment>
          </ObservedIn>
          <ObservedIn>
            <Sample>
              <Origin>not applicable</Origin>
              <Tissue>Skin fibroblasts</Tissue>
              <CellLine>FB861</CellLine>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>not applicable</AffectedStatus>
              <Gender>male</Gender>
            </Sample>
            <Method>
              <Description>Alpha- and beta-subunit TFP protein was examined by SDS-PAGE and western blotting.</Description>
              <MethodType>in vitro</MethodType>
              <ObsMethodAttribute>
                <Attribute Type="MethodResult">Significant decrease of alpha-TFP subunit protein and almost absence of beta-TFP subunit protein</Attribute>
              </ObsMethodAttribute>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
            <Comment>The presence of a truncating HADHB mutation - point deletion with frameshift - caused a decrease in both TFP subunits in this compound heterozygous individual.</Comment>
          </ObservedIn>
          <ObservedIn>
            <Sample>
              <Origin>not applicable</Origin>
              <Tissue>Skin fibroblasts</Tissue>
              <CellLine>FB861</CellLine>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>not applicable</AffectedStatus>
              <Gender>male</Gender>
            </Sample>
            <Method>
              <Description>Oxygen consumption rate (OCR) of skin fibroblasts was measured with a Seahorse XFe96 Extracellular Flux Analyzer.</Description>
              <MethodType>in vitro</MethodType>
              <ObsMethodAttribute>
                <Attribute Type="MethodResult">Reduction of maximal respiration (oxygen consumption rate - OCR: 186.7 pmol/min/mg protein/mL) and spare respiratory capacity (97.0) compared to control fibroblasts (460.0 and 355.1, respectively).</Attribute>
              </ObsMethodAttribute>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
            <Comment>Significant derangement of mitochondrial bioenergetics</Comment>
          </ObservedIn>
          <ObservedIn>
            <Sample>
              <Origin>not applicable</Origin>
              <Tissue>Skin fibroblasts</Tissue>
              <CellLine>FB861</CellLine>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>not applicable</AffectedStatus>
              <Gender>male</Gender>
            </Sample>
            <Method>
              <Description>Acylcarnitines were analyzed by ESI-MS/MS (precursor-ion scan of m/z 85 mode) and quantitated by comparison to isotope-labelled internal standards.</Description>
              <MethodType>in vitro</MethodType>
              <ObsMethodAttribute>
                <Attribute Type="MethodResult">Increased levels of 3-hydroxypalmitoylcarnitine (C16-OH) - 0.440 mcM/mg protein/mL - in fibroblast culture media after a palmitate load compared to control cells (0.100).</Attribute>
              </ObsMethodAttribute>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
            <Comment>Significant elevation of the primary marker of mitochondrial trifunctional protein deficiency, C16-OH</Comment>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HADHB">
              <Name>hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta</Name>
            </Gene>
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <GeneLocation>NM_000183.3:exon 9</GeneLocation>
          </Location>
          <OtherNameList>
            <Name Type="SubmitterVariantId">HGMD:CD031504</Name>
            <Name>p.A232Lfs*20</Name>
            <Name>g.36028del</Name>
          </OtherNameList>
          <FunctionalConsequence Value="RNA degradation by nonsense-mediated decay">
            <XRef DB="Variation Ontology" ID="0347" URL="http://purl.obolibrary.org/obo/VariO_0347" />
          </FunctionalConsequence>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000183.3:c.693del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="609015" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11779637</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="4984950" TraitType="Finding" MappingType="XRef" MappingValue="HP:0045045" MappingRef="HP">
        <MedGen CUI="C4073171" Name="Elevated circulating acylcarnitine concentration" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4984950" TraitType="Disease" MappingType="XRef" MappingValue="609015" MappingRef="OMIM">
        <MedGen CUI="CN376812" Name="Mitochondrial trifunctional protein deficiency 1" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4984950" TraitType="Finding" MappingType="XRef" MappingValue="HP:0009830" MappingRef="HP">
        <MedGen CUI="C0031117" Name="Peripheral neuropathy" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4984950" TraitType="Finding" MappingType="XRef" MappingValue="HP:0001985" MappingRef="HP">
        <MedGen CUI="C1856438" Name="Hypoketotic hypoglycemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4984950" TraitType="Finding" MappingType="XRef" MappingValue="HP:0003236" MappingRef="HP">
        <MedGen CUI="C0241005" Name="Elevated circulating creatine kinase concentration" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4984950" TraitType="Finding" MappingType="XRef" MappingValue="HP:0003201" MappingRef="HP">
        <MedGen CUI="C0035410" Name="Rhabdomyolysis" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4984950" TraitType="Finding" MappingType="XRef" MappingValue="HP:0001252" MappingRef="HP">
        <MedGen CUI="C0026827" Name="Hypotonia" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

